TEVA Teva Pharmaceutical Industries Ltd

By Sabela Ojea

Teva Pharmaceutical Industries Ltd. has received U.S. Food and Drug Administration approval for its Austedo Xr medication, which treats a range of uncontrollable muscle movements associated with Huntington's Disease.

The generic-drug maker said the FDA has approved Austedo Xr's extended-release tablets, a new once-daily formula for adults diagnosed with tardive dyskinesia and chorea.

Huntington's Disease is a rare and inherited progressive neurological disorder that causes nerve cells in parts of the brain to gradually break down and die.

Shares inched up 0.5% to $10.11 in after-hours trading.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

February 17, 2023 17:48 ET (22:48 GMT)

Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024